Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
KIROMIC BIOPHARMA INC (KRBP)
Company Research
Source: Business Wire
Follow-up Findings Show Stable DiseaseFDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with DeltacelFast Track Designation Request Submitted to FDAComplete Enrollment in Trial’s Second Cohort Expected in July HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.The third and fourth patients showed stable disease at their four- and two-month follow-up visits, respectively. Both patients are doing well, and neither showed any dose-limiting toxicities. Patients three and four are being treated at the Beverly Hills Cancer Center (BHCC).The second patient, also being treat
Show less
Read more
Impact Snapshot
Event Time:
KRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRBP alerts
High impacting KIROMIC BIOPHARMA INC news events
Weekly update
A roundup of the hottest topics
KRBP
News
- Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialBusiness Wire
- Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous RecommendationBusiness Wire
- Kiromic BioPharma’s Deltacel Receives FDA Fast Track DesignationBusiness Wire
- Kiromic reports update from Phase I NSCLC treatment trial [Yahoo! Finance]Yahoo! Finance
- Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial [Yahoo! Finance]Yahoo! Finance
KRBP
Sec Filings
- 8/26/24 - Form 4
- 8/21/24 - Form 4
- 8/14/24 - Form 4
- KRBP's page on the SEC website